“初发”及左旋多巴治疗的帕金森病患者与对照组的血小板单胺氧化酶B活性
Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
作者信息
Kuhn W, Müller T, Gerstner A, Winkel R, Goetz M E
机构信息
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Germany.
出版信息
Can J Neurol Sci. 1998 Aug;25(3):249-51. doi: 10.1017/s0317167100034090.
OBJECTIVE
Previous studies demonstrated controversial results regarding monoamine oxidase B (MAO-B) activity in platelets in the periphery in parkinsonian patients (PD).
SUBJECTS AND METHODS
Therefore we determined platelet MAO-B activity in three age- and sex-matched groups of 17 untreated, so called "de novo" patients with Parkinson's disease (PD), 17 parkinsonian patients, receiving levodopa, and 17 controls by a radio enzymatic assay.
RESULTS
No significant differences of MAO-B activity appeared.
CONCLUSION
This result suggests that phenotypic determination of MAO-B activity in platelets may not be used as peripheral marker in PD and that levodopa treatment does not alter MAO-B activity in the periphery.
目的
先前的研究表明，帕金森病（PD）患者外周血小板中单胺氧化酶B（MAO - B）活性的结果存在争议。
受试者与方法
因此，我们通过放射酶法测定了三组年龄和性别匹配的人群的血小板MAO - B活性，其中包括17名未经治疗的所谓“初发”帕金森病（PD）患者、17名正在接受左旋多巴治疗的帕金森病患者以及17名对照者。
结果
MAO - B活性未出现显著差异。
结论
该结果表明，血小板中MAO - B活性的表型测定可能无法用作PD的外周标志物，且左旋多巴治疗不会改变外周的MAO - B活性。
Zotero 插件